02511 君聖泰醫藥 - B
HIGHTIDE-B
HIGHTIDE-B
| Listing Date | 2023/12/22 |
| Listing Price | 11.500 |
Quote
Subscription Result
- Subscription Rate32.22x
- Guarantee One Lot Size9 lot
- One Lot Success Rate13.65%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
HighTide Therapeutics is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases.
--
The group have researched and developed in-house a pipeline with five proprietary drug candidates covering nine indications, including five indications that are at clinical stage. Its Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
--
As of 4 December 2023, the group held 133 patents and patent applications, including 58 patents and patent applications in relation to its Core Product and held 34 trademarks and trademark applications in the United States, Mainland China, Hong Kong, Europe and United Kingdom.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 24.19M shares |
| No. of International Offer Shares | 16.94M shares |
| No. of HK Offer Shares | 7.26M shares |
| Offer Price | $11.50 |
| Stock Code | 2511 |
| Sponsor(s) | UBS Securities Hong Kong Limited, Huatai Financial Holdings (Hong Kong) Limited |
| Underwriter(s) | UBS AG Hong Kong Branch, Huatai Financial Holdings (Hong Kong) Limited, CLSA Limited, CMB International Capital Limited, BOCOM International Securities Limited, Yue Xiu Securities Company Limited, CCB International Capital Limited, Fosun International Securities Limited, Goldlink Securities Limited, I Win Securities Limited, Shenwan Hongyuan Securities (H.K.) Limited, uSmart Securities Limited, Winbull Securities International (HK) Limited |
TIME TABLE
| Application Period | Dec 14 (Thu) - noon, Dec 19 (Tue) |
| Price Determination Date | -- |
| Result Announcement Date | On or before Dec 21 (Thu) |
| Result Announcement Date | On or before Dec 21 (Thu) |
| Result Announcement Date | On or before Dec 22 (Fri) |
| Dealings in Shares commence on | Dec 22, 2023. (Fri) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $11.50 |
| Capitalization | 5.92B |
| NAV / share ($) | $1.91 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 11.50, the net proceeds raised would be HKD 194.10M, of which |
| 80% : Clinical development activities and registration filings of Core Product HTD1801 |
| 5% : Research and development, drug production for the clinical studies of product candidate HTD1804 for obesity |
| 10% : For the early drug discovery and development of other drug candidates |
| 5% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).